Highlights

In brief

High throughput sequencing techniques reveal that RNA-RNA structures are generally conserved between SARS-CoV-2 variants, including the ultra-long-range interacting structure LR1, which recruits host protein ADAR1 to enhance replication.

Photo by kjpargeter | Freepik

A structural weakness in COVID-19?

9 Mar 2026

A unique RNA structure shared across SARS-CoV-2 variants may contribute to viral fitness, offering a potential target for new antiviral treatments.

Thanks to movies like Jurassic Park, DNA and RNA molecules may be best known as coding sequences used to build a living creature. For some viruses, however, these nucleic acids are more than just pages of instructions; they’re also critical tools that enable them to infiltrate and hijack a host cell, forcing it to produce more viral particles.

Since emerging in 2019, the SARS-CoV-2 virus—perhaps the most infamous RNA virus today—has evolved into several different variants, each carrying mutations that set them apart from the original strain. Researchers such as A*STAR Genome Institute of Singapore (A*STAR GIS) Senior Scientist Siwy Ling Yang are keen to learn just how these mutations alter the shapes of viral RNA, thereby boosting (or reducing) a strain’s ability to survive and reproduce.

“Like proteins, RNAs can fold into complex shapes to perform various functions. These shapes are particularly important in RNA viruses, as they use RNA to interact with both their own genomes and with host RNA,” said Yang.

In a recent investigation into links between genome structure and function across SARS-CoV-2 variants, Yang worked alongside Yue Wan, a Principal Investigator at A*STAR GIS; Roland Huber, Principal Scientist at the A*STAR Bioinformatics Institute (A*STAR BII); and Andres Merits of the University of Tartu, Estonia. The team included colleagues from A*STAR GIS; A*STAR Infectious Diseases Labs (A*STAR IDL); A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB); Duke-NUS Medical School, Singapore; and the University of California in the US.

The researchers focused on a key component of RNA shape: a connection known as long-range RNA-RNA pairing. “Imagine such a pairing as a long piece of string with Velcro patches placed near both ends, which then make contact and stick together,” said Wan. “The resulting carefully folded shapes allow viruses to control protein production, genome copying and packaging using molecular structure, rather than extra genes.”

Using high-throughput structure-probing techniques to process multiple samples simultaneously, the team modelled and compared the genomes of wild-type SARS-CoV-2 with the Alpha, Beta, Delta and Omicron variants to identify shared structures linked to viral fitness.

SHAPE-MaP modelling revealed that across all strains, SARS-CoV-2 RNA structures could fold into many complex shapes, with structures generally unchanged between variants. However, even single-nucleotide variations or interactions with RNA-binding proteins could impact RNA shapes in all strains.

“Interestingly, we also discovered that a shared ultra-long-range RNA-RNA interacting structure, LR1, binds directly to a host protein called ADAR1,” said Huber. “This binding appears to facilitate edits on the viral genome that enable more successful proliferation.”

The team also found that disrupting LR1 decreased virus replication in host cells, and that LR1 seemed to bind to SARS-CoV-2’s protein shell, hinting at a potential role in packaging the viral genome.

These results highlight the functional impact of RNA structures in SARS-CoV-2 and may help direct treatment research. “Understanding the RNA architecture of SARS-CoV-2 provides critical insights into how the virus maintains infectivity despite mutations,” said Yang. “These discoveries could inform the development of next-generation therapeutics aimed at destabilising viral RNA structures, rather than targeting proteins alone.”

The A*STAR-affiliated researchers contributing to this research are from the A*STAR Genome Institute of Singapore (A*STAR GIS), A*STAR Bioinformatics Institute (A*STAR BII), A*STAR Infectious Diseases Labs (A*STAR IDL) and A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB).

Want to stay up to date with breakthroughs from A*STAR? Follow us on Twitter and LinkedIn!

References

Yang, S.L., DeFalco, L., Wang, S., Wong, Y.H., Han, J., et al. A conserved long-range RNA interaction in SARS-CoV-2 recruits ADAR1 to enhance virus proliferation. Nature Communications 16, 8460 (2025). | article

About the Researchers

Yue Wan received her PhD degree in cancer biology from Stanford University, US, under the mentorship of Howard Y. Chang, where she developed a high-throughput method for probing genome-wide RNA structures. She is currently a Principal Investigator at the Genome Institute of Singapore (GIS). She was previously a Society in Science-Branco Weiss Fellow, an EMBO Young Investigator and a CIFAR-Azrieli Global Scholar. In 2015, she was honoured with the Young Scientist Award at the President’s Science and Technology Awards in Singapore, followed by the L’Oréal-UNESCO for Women in Science, Singapore National Fellowship in 2016. Wan's research focuses on functional RNA structures and their roles in cellular biology regulation.
Siwy Ling Yang is currently a Senior Scientist at the A*STAR Genome Institute of Singapore (A*STAR GIS) under Yue Wan’s laboratory. She obtained her PhD degree in plant pathology from the University of Florida, US, in 2013 by studying the stress signalling, pathogenicity and development of Alternaria alternata in citrus. She joined A*STAR in 2014 at the A*STAR Institute of Molecular and Cell Biology (A*STAR IMBC) to study human fungal pathogen Candida albicans biology under Yue Wang. Since 2017, she has transitioned into the field of RNA genomics and structure under Dr. Wan Yue’s (GIS) supervision. Her current research focus is on functional RNA structures and their roles in cellular biology regulation.
Roland Huber is a Principal Investigator for Structure and Function of RNA and program lead for AI and Emerging Technologies at the A*STAR Bioinformatics Institute (A*STAR BII). Huber studied computational biology at the University of Innsbruck, Austria, and Yale University, US. His research focuses on the interplay of structure and function of RNA in diseases, nucleic acid therapeutics development and RNA manufacturing. Using statistical modelling, machine learning, multi-omics data and molecular simulations, Huber’s team investigates functional mechanisms of folded RNA and RNA-protein complexes, including how to use RNA as a drug and RNA as a drug target. Therapeutic areas of interest comprise tropical and emerging infectious diseases and cancer. Huber’s team also works on biotechnological problems of RNA manufacturing and delivery.

This article was made for A*STAR Research by Wildtype Media Group